AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1532336
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly amorolfine 5% nail lacquer
Trial: 29659913
Drug: Hydromorphone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (4 mg/day initially, adjusted as necessary)
Trial: 29659913
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride (10 mg/day initially, adjusted as necessary)
Trial: 27801825
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement containing 600 mg of α‐lipoic acid, 165 mg of L‐carnosin, 7.5 mg of zinc, and vitamins of group B
Trial: 19929980
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 mg/d, titrated to 300 mg/day)
Trial: 19929980
Drug: Hydrochlorothiazide (HCTZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ, 12.5 mg/d, titrated to 25 mg/day)
Trial: 16636232
Drug: IV recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV recombinant tissue plasminogen activator (rt‐PA) 0.9 mg/kg
Trial: 10807491
Drug: Venlafaxine 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 375 mg/day
Trial: 9085388
Drug: Annual tuberculin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual tuberculin testing plus isoniazid (INH) preventive therapy
Trial: 8138865
Drug: Combined behavioral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined behavioral therapy (relaxation training, temperature biofeedback, cognitive training)
Trial: 8138865
Drug: Combined behavioral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined behavioral therapy
Trial: 26698911
Drug: Myo-inositol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (2 g plus 200 μg folic acid twice a day)
Trial: 26698911
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 μg folic acid twice a day)
Trial: 21612646
Drug: donepezil 23
RxNorm normalized name: donepezil 23 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donepezil 23 mg/d
Trial: 20826962
Drug: Etomidate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.2 mg/Kg
Trial: 20826962
Drug: Midazolam 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.15 mg/Kg
Trial: 20826962
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg/Kg
Trial: 20826962
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg/Kg
Trial: 18796471
Drug: Amiodarone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (300 mg intravenous bolus after third unsuccessful shock)
Trial: 16155274
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Zn/d
Trial: 10078604
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HAV vaccination (25 units) at 0 and 24 weeks (Group 1)
Trial: 10078604
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of HAV vaccination (25 units) at 0, 2, and 24 weeks (Group 2)
Trial: 1869643
Drug: Controlled-release styrene-divinylbenzene
RxNorm normalized name: divinylbenzene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release styrene-divinylbenzene polymer system containing benzoyl peroxide
Trial: 1869643
Drug: Topical lotion
RxNorm normalized name: Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lotion with freely dispersed benzoyl peroxide
Trial: 1869643
Drug: Formulations containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations containing entrapped benzoyl peroxide
Trial: 7267678
Drug: hydrotalcite/dimethicone suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrotalcite/dimethicone suspension
Trial: 7267678
Drug: magnesium hydroxide/aluminum
RxNorm normalized name: magnesium hydroxide/aluminum hydroxide 170-180 ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: magnesium hydroxide/aluminum hydroxide suspension
Trial: 6741447
Drug: Paracetamol 500
RxNorm normalized name: Paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg suppositories
Trial: 6741447
Drug: Pentazocine 50
RxNorm normalized name: pentazocine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 50 mg suppositories
Trial: 6741447
Drug: Pentazocine 50
RxNorm normalized name: pentazocine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 50 mg suppositories after halothane anaesthesia
Trial: 6741447
Drug: Pentazocine 50
RxNorm normalized name: pentazocine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 50 mg suppositories after enflurane anaesthesia
Trial: 6741447
Drug: Paracetamol 500
RxNorm normalized name: Paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg suppositories after enflurane anaesthesia
Trial: 6741447
Drug: Paracetamol 500
RxNorm normalized name: Paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg suppositories after halothane anaesthesia
Trial: 29843528
Drug: Writing about
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Writing about daily events
Trial: 23617557
Drug: One-step method
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step method (2-h, 75 g oral glucose tolerance test)
Trial: 23617557
Drug: Two-step method
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-step method (50 g glucose challenge test followed by 100 g OGTT)
Trial: 23588128
Drug: Self-administered paper-and-pencil
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered paper-and-pencil questionnaire measuring perceived risk for STIs
Trial: 21174921
Drug: No steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroids (Control group)
Trial: 19094438
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg levobupivacaine 0.5% mixed with 25 microg fentanyl (group LF)
Trial: 19094438
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg levobupivacaine 0.5% (group L)
Trial: 10924301
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium (10.3 mmol)
Trial: 10924301
Drug: Sotalol and
RxNorm normalized name: sotalol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol and oral magnesium
Trial: 1529944
Drug: Treatment trial
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment trial
Trial: 3981321
Drug: Preterm milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preterm milk with iron supplementation (2 mg/kg/day)
Trial: 3981321
Drug: Mature human
RxNorm normalized name: Immature human tripeptidyl-peptidase 1
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mature human milk with iron supplementation (2 mg/kg/day)
Trial: 3981321
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula with iron supplementation (2 mg/kg/day)
Trial: 26902092
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of dried plum
Trial: 26902092
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g of dried plum
Trial: 24525660
Drug: Tianeptine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (37.5 mg/d)
Trial: 22463596
Drug: Good adherence
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good adherence (never missed pills in the last month)
Trial: 22463596
Drug: 100% Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% Drug Possession Ratio (DPR) throughout the first year
Trial: 22463596
Drug: Poor adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor adherence subgroup by Drug Possession Ratio (DPR)
Trial: 16167789
Drug: PGE1 (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 (0.05 microg x kg(‐1) x min(‐1) administered intravenously during surgery)
Trial: 16167789
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PGE1 administration)
Trial: 12800126
Drug: Nicotine-replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine-replacement therapy and bupropion
Trial: 10992178
Drug: Postoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative administration of low-dose cyclic oral contraceptives for 6 months
Trial: 8833056
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (MTX 5/50-7.5/100 mg/week/day)
Trial: 8833056
Drug: Azathioprine (AZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (AZA 50-150 mg/day)
Trial: 8833056
Drug: Methotrexate (MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX 5-15 mg/week)
Trial: 8833056
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment and AZA
Trial: 1459383
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment for first 3 months)
Trial: 23175563
Drug: DHP +
RxNorm normalized name: DHP ether
DrugBank: Dihematoporphyrin ether (DB15351)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHP + primaquine (0.75 mg/kg single dose on day 3)
Trial: 18433844
Drug: Simvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (80 mg/day for 5 days)
Trial: 18433844
Drug: Rosuvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (40 mg/day for 5 days)
Trial: 14677161
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) + stretching exercises
Trial: 1727902
Drug: Intravenous 2',3'-dideoxyinosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 2',3'-dideoxyinosine (ddI)
Trial: 1727902
Drug: Oral 2',3'-dideoxyinosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 2',3'-dideoxyinosine (ddI)
Trial: 6724661
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein supplement (58 g/day of a 60:40 mixture of soy and wheat proteins)
Trial: 6724661
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein supplement (7 g/day of rice protein)
Trial: 26551600
Drug: Mother-infant psychoanalytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mother-infant psychoanalytic treatment (MIP) group
Trial: 19720342
Drug: Herbal drug
RxNorm normalized name: herbal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal drug (500 mg of saffron, celery seed, and anise extracts three times a day for three days)
Trial: 8788323
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral treatment program (SBT)
Trial: 7350310
Drug: Sucrose electrolyte
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose electrolyte oral solution
Trial: 7350310
Drug: Glucose electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose electrolyte oral solution
Trial: 30755381
Drug: IA‐TXA (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA‐TXA (15 mg/kg)
Trial: 30755381
Drug: IV‐TXA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV‐TXA (10 mg/kg)
Trial: 30755381
Drug: IA‐TXA (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA‐TXA (15 mg/kg) and IV‐TXA (10 mg/kg)
Trial: 23582675
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of darbepoetin-alpha (DA) 150 μg
Trial: 19207722
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine tablet
Trial: 11370797
Drug: Losartan (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50-100 mg/day) for 12 weeks
Trial: 9198730
Drug: Dexfenfluramine (dF)
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine (dF) 15 mg bid
Trial: 8458924
Drug: Oestradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol valerate 6 mg per os daily + intravaginal micronized progesterone 600 mg daily
Trial: 8458924
Drug: Intravaginal micronized
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal micronized progesterone 600 mg daily
Trial: 3007984
Drug: Intravenous cytomegalovirus
RxNorm normalized name: cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cytomegalovirus immune globulin and seronegative blood products
Trial: 30590410
Drug: mAHTPred (meta-predictor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAHTPred (meta-predictor using ensemble learning of four ML algorithms)
Trial: 22675968
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium suppositories (100 mg/day)
Trial: 22675968
Drug: Indomethacin suppositories
RxNorm normalized name: Indomethacin Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppositories (100 mg/day)
Trial: 20099281
Drug: Lowest level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest level of methylation in LINE‐1 among CC carriers for the MTRR Ex5+123C>T polymorphism
Trial: 17509235
Drug: Dapsone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone (200 mg single dose)
Trial: 12060479
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of tazarotene and mometasone furoate
Trial: 12060479
Drug: All topical
RxNorm normalized name: Rexall Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All topical therapy regimens
Trial: 8789310
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy with omeprazole, bismuth, tetracycline and metronidazole for 1 week (pretreated with omeprazole for 3 days)
Trial: 8789310
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with omeprazole and amoxicillin for 2 weeks
Trial: 1872398
Drug: Graded balloon
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded balloon distensions (1 min duration at 10-min intervals in 8-ml stepwise increments)
Trial: 21332375
Drug: VR-graded exposure
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR-graded exposure therapy (VR-GET)
Trial: 19178390
Drug: TTFC administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFC administered in the evening
Trial: 19178390
Drug: TTFC administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFC administered in the morning
Trial: 17578973
Drug: Extended-release epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release epidural morphine (EREM) 10 mg
Trial: 17578973
Drug: Conventional epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional epidural morphine 4 mg
Trial: 15190961
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 2, 4, and 6 microg x kg(‐1) x min(‐1)
Trial: 11464357
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.75% ropivacaine plus 0.5 mL of 0.9% NaCl (solution A)
Trial: 11464357
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.75% ropivacaine plus 0.0012 mEq of NaHCO(3) (solution B)
Trial: 11464357
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.75% ropivacaine (with adrenaline) plus 0.015 mEq of NaHCO(3) (solution C)
Trial: 25808588
Drug: TNF-α inhibitors
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNF-α inhibitors (adalimumab, infliximab, etanercept, certolizumab pegol, golimumab)
Trial: 18328151
Drug: Back school
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back school program (five-weekly sessions)
Trial: 18328151
Drug: Weekly medical
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly medical visits (control group)
Trial: 16691029
Drug: Fluvastatin XL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin XL, 80 mg, morning administration
Trial: 16691029
Drug: Fluvastatin XL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin XL, 80 mg, evening administration
Trial: 8665116
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (1 mg norethindrone and 35 micrograms ethinyl oestradiol) for 21 days, n = 7
Trial: 1387301
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral tablet formulation 1
Trial: 1387301
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral tablet formulation 2
Trial: 1387301
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of the lactobionate salt
Trial: 1387301
Drug: Oral dosing
RxNorm normalized name: oral dosing devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of clarithromycin
Trial: 29284534
Drug: Perineural catheter
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perineural catheter (PNC) with continuous local anaesthetic infusion for the first 5 postoperative days
Trial: 24330343
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oxymorphone ER after a high-fat meal
Trial: 24330343
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oxymorphone ER after fasting
Trial: 21117499
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product Lipivim (200 mg fenofibrate)
Trial: 21117499
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (200 mg fenofibrate)
Trial: 17212680
Drug: Diclofenac epolamine
RxNorm normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac epolamine (DHEP) 65-mg sachet
Trial: 781495
Drug: Prindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prindolol (10 mg three times per day)
Trial: 781495
Drug: Prindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prindolol (10 mg three times per day) + Hydrochlorothiazide (50 mg per day)
Trial: 21845501
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (gpc training for oral reading and spelling, orthographic spelling strategy, RAP training, morphological strategies)
Trial: 21845501
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (gpc training for oral reading and phonological awareness, continued step 2 training, orthographic spelling strategy training)
Trial: 21845501
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (RAP training during step 3)
Trial: 22123798
Drug: Internet-delivered intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Internet-delivered intervention (quarterly educational modules, practice guidelines, monthly literature summaries, automated e-mail reminders) for 27 months